Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic

1987 ◽  
Vol 39 (S1) ◽  
pp. 31-35 ◽  
Author(s):  
G. R. C. McLeod ◽  
D. B. Thomson ◽  
P. Hersey
Keyword(s):  
Malignant Melanoma ◽  
Phase I ◽  
Interferon Alfa ◽  
Recombinant Interferon ◽  
Advanced Malignant Melanoma

Three consecutive phase II studies of recombinant interferon alfa–2a in advanced malignant melanoma. Updated analyses

Cancer ◽  
1987 ◽  
Vol 59 (S3) ◽  
pp. 638-646 ◽  
Author(s):  
Edward T. Creagan ◽  
David L. Ahmann ◽  
Stephen Frytak ◽  
Harry J. Long ◽  
M. N. Chang ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Interferon Alfa ◽  
Recombinant Interferon ◽  
Phase Ii Studies ◽  
Advanced Malignant Melanoma ◽  
Consecutive Phase

scholarly journals A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

2015 ◽  
Vol 20 (6) ◽  
pp. 617-618 ◽  
Author(s):  
Ryan J. Sullivan ◽  
Nageatte Ibrahim ◽  
Donald P. Lawrence ◽  
Julie Aldridge ◽  
Anita Giobbie‐Hurder ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase I ◽  
Phase I Trial ◽  
Advanced Malignant Melanoma

Role of recombinant interferon alpha2 and cimetidine in patients with advanced malignant melanoma

1988 ◽  
Vol 114 (1) ◽  
pp. 108-109 ◽  
Author(s):  
Tariq I. Mughal ◽  
William A. Robinson ◽  
M. Roy Thomas ◽  
Robert Spiegel
Keyword(s):  
Malignant Melanoma ◽  
Recombinant Interferon ◽  
Advanced Malignant Melanoma

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.

1995 ◽  
Vol 13 (11) ◽  
pp. 2776-2783 ◽  
Author(s):  
E T Creagan ◽  
R J Dalton ◽  
D L Ahmann ◽  
S H Jung ◽  
R F Morton ◽  
...  
Keyword(s):  
Treatment Group ◽  
High Risk ◽  
Malignant Melanoma ◽  
Group Versus ◽  
Interferon Alfa ◽  
Stage I ◽  
Stage Ii ◽  
Control Group ◽  
Recombinant Interferon ◽  
Ifn Alpha

PURPOSE We conducted a randomized prospective trial in selected patients with fully resected high-risk stage I and II malignant melanoma. PATIENTS AND METHODS Interferon alfa-2a (IFN-alpha 2a) 20 x 10(6) U/m2 was administered three times each week for 12 weeks by the intramuscular route. Both the treatment group (n = 131) and the control group (n = 131) were evenly balanced with regard to relevant prognostic discriminants. RESULTS The median disease-free survival (DFS) time was 2.4 years for the IFN-alpha 2a group and 2.0 years for the observation group (log-rank P = 0.19). The median survival times were 6.6 years for IFN-alpha 2a and 5.0 years for observation (log-rank P = .40). For stage I patients (n = 102), there was no apparent therapeutic advantage from IFN-alpha 2a therapy. The DFS for stage II patients was a median of 10.8 months in the control group versus 17 months in the treatment group. The overall survival time was 4.1 years for the treatment group versus 2.7 years for the control group. The differences in DFS for stage II patient were significant in a Cox model. These results must be interpreted cautiously because of subset analysis. A severe flu-like toxicity occurred in 44% of patients, 13% lost at least 10% of their baseline weight, and 45% experienced a worsening of Eastern Cooperative Oncology Group (ECOG) performance score. CONCLUSION Our findings indicate trends that suggest a possible benefit for selected patients with high-risk malignant melanoma. The results will require further study in a larger patient population for confirmation.

Recombinant interferon alfa therapy for acute non-A, non-B hepatitis: A phase I/II study

1991 ◽  
Vol 13 ◽  
pp. S75
Author(s):  
N. Tassopoulos ◽  
P. Zorbas ◽  
Th. Giannikakis ◽  
M. Koutelou ◽  
A. Todoulos ◽  
...  
Keyword(s):  
Phase I ◽  
Hepatitis A ◽  
Interferon Alfa ◽  
Recombinant Interferon

Phase I & Ib Trials of Murine Tyrosinase ± Human GM-CSF DNA Vaccination in Dogs with Advanced Malignant Melanoma

2005 ◽  
Vol 3 (1) ◽  
pp. 35-36
Author(s):  
P. J. Bergman ◽  
M. A. Camps-Palau ◽  
J. A. McKnight ◽  
N. F. Leibman ◽  
C. A. Novosad ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase I ◽  
Dna Vaccination ◽  
Gm Csf ◽  
Advanced Malignant Melanoma
Sign in / Sign up

Export Citation Format

Share Document